The present invention relates to the field of implantable stents having flexibly connected adjacent stent elements.
The use of implantable stents in the vasculature and other body conduits has become commonplace since first proposed by Dotter in the 1960's. These devices are required to have a small, compacted diameter for insertion into an intended body conduit and transport, typically via a catheter, to a desired site for deployment, at which site they are expanded to a larger diameter as necessary to fit interferably with the luminal surface of the body conduit. Balloon expandable stents are expanded by plastically deforming the device with an inflatable balloon on which the expandable stent was previously mounted in the compacted state, the balloon being attached to the distal end of the catheter and inflated via the catheter. Self-expanding stents are forcibly compacted to a small diameter and restrained at that diameter by a constraining sleeve or other means. Following delivery to a desired site for deployment, they are released from the restraint and spring open to contact the luminal surface of the body conduit. These devices are typically made from nitinol metal alloys and typically rely on the superelastic and biocompatible character of this metal. Nitinol stents that rely on the shape memory attributes of that material are also known.
The evolution of implantable stents has also included the use of a tubular covering fitted to the stent, either to the outer surface, the luminal surface or to both surfaces of the stent. These covered stents have generally come to be referred to as stent-grafts. The coverings are generally of a polymeric biocompatible material such as polyethylene terephthalate (PET) or polytetrafluoroethylene (PTFE). See, for example, U.S. Pat. No. 4,776,337 to Palmaz.
The Palmaz '337 patent also describes that the covering may be optionally provided with perforations if desired for particular applications. Because of the open area provided by the perforations, such devices having perforated coverings may be considered to be a sort of hybrid stent and stent-graft, as are devices that include stent frames having metallic stent elements and polymeric elements connecting, covering or other otherwise being attached to the stent elements. The presence of the polymeric elements reduces the otherwise open space between the adjacent metallic stent elements, either very slightly or very substantially depending on the intended application and mechanical design. Perforated stent-grafts are also described elsewhere; see, for example WO00/42949.
Stents having stent elements provided with polymeric coatings or coverings are also known; see, for example, U.S. Pat. No. 5,735,892 to Myers et al. and U.S. Pat. No. 5,968,091 to Pinchuk et al.
Generally, a fully covered stent-graft can be considered to have a surface area (hereinafter Amax) equal to the outer circumference of the expanded stent multiplied by the length of the stent. For a conventional, open frame stent (as opposed to a stent-graft), the surface area represented by all of the stent elements is only a small portion of the maximum surface area Amax. The actual surface area covered by the stent, meaning the area covered by all components of the stent (including connecting elements) in their deployed state, is Astent. The porosity index, or P.I., describes the open area (the portion of the maximum surface area not covered by all components of the stent assembly) as a percentage of maximum surface area, wherein:
P.I.=(1−(Astent/Amax))×100%.
A preferred method of measuring the actual surface area covered by the stent (Astent), involves the use of a machine provided Visicon Inspection Technologies, LLC (Napa, CA). The Visicon Finescan™ Stent Inspection System (Visicon Finescan machine model 85) uses a 6000 pixel line scan camera to generate a flat, unrolled view of a stent. In operation, the stent is mounted on a sapphire mandrel with a fine diffuse surface. This mandrel is held under the linear array camera and rotated by the system electronics and is used to trigger the linear array camera to collect a line of image data in a precise line-by-line manner. After a complete revolution an entire image of the stent is acquired. When the entire stent has been imaged, the software differentiates between the stent with cover and the background. The total number of picture elements (pixels) is compared to the total number of pixels associated with the stent and cover to determine Astent. Basic settings on the machine used for this type of determination are (for example): light, 100%; exposure, 0.3 ms/line; gain, 5; threshold, 50; noise filter, 20; smoothing, 4.
The open area may be a continuous single space, such as the space between windings of a single helically wound stent element. Likewise the open area may be represented by the space between multiple individual annular or ring-shaped stent elements. The open area may also be represented by the total area of multiple apertures provided by either a single stent element (e.g., as shown by
Stents having a porosity index of greater than 50% are considered to be substantially open stents.
In addition to the porosity index, the size of any aperture providing the open area must be considered if it is intended to cover only a portion of a stent area for a specific stent application. For multiple apertures, often the consideration must be for the largest size of any individual aperture, particularly if the apertures are to provide for a “filtering” effect whereby they control or limit the passage of biologic materials from the luminal wall into the flow space of the body conduit.
Various stent devices combining metallic stent elements with polymeric connecting elements are known; see, for example U.S. Pat. No. 5,507,767 to Maeda et al. Another is a stent provided with a flexible knitted sleeve having small open apertures in the fashion of chain link fencing, from InspireMD Ltd. (4 Derech Hashalom St., Tel Aviv 67892 Israel).
An open stent (a stent having open space through its thickness at locations between the ends of the stent) and method of making are described. The stent incorporates flexible, preferably polymeric connecting elements (i.e., polymeric webs) into the stent wherein these connecting elements connect adjacent, spaced-apart stent elements. The flexible, preferably polymeric connecting elements provide a means for keeping the stent elements equally spaced and allow the construction of a stent having good flexibility and a useful resistance to forces that may be applied to the device in vivo such as torsional forces, bending forces, axial tension or compression, or radial compression.
Preferably the spaced-apart adjacent stent elements are in the form of a helically wound serpentine wire having space provided between adjacent windings. Other stent forms such as multiple, individual spaced-apart ring-shaped stent elements may also be used. Ring shaped stent elements may be in the form of zig-zag elements creating a circumferential ring, or interconnected elements that provide diamond shaped openings in a circumferential sequence when the device is diametrically expanded. Alternatively, embodiments presented that utilize the helically wound serpentine forms are preferred for many applications. The stent is preferably self-expanding (made from materials such as nitinol) but may also be made from materials suitable for balloon expandable stents (e.g., stainless steel, magnesium based alloys, magnesium, cobalt chromium alloy, titanium or titanium based alloys).
Helically wound stent frames are inherently unstable in absence of a secondary linkage connecting adjacent rows. Utilization of the described polymer web linkage to interconnect adjacent rows stabilizes the helical structure and limits axial elongation, torsion and bending while allowing a high degree of flexibility.
The adjacent, spaced-apart stent elements are preferably substantially circumferentially oriented, meaning that they have a general direction of orientation perpendicular to the longitudinal axis of the stent, when the stent is in a straight, unbent state.
A method of making involves the application of a biocompatible polymeric covering to the chosen stent form to create, temporarily, a stent-graft. The covering is preferably of a strong and thin material and may be in a tubular form, although sheet forms (e.g., relatively wide films cut into narrow tapes) are preferred for manufacturing as will be described. The covering is preferably applied to the outer surface of the stent, but may be applied only to the luminal surface, or alternatively may be applied to both the luminal and abluminal (outer) surfaces of the stent. Covering both the luminal and abluminal surfaces allows for the possibility of covering substantially all of the metallic surfaces of the stent with the desired polymer. The polymeric film covering is preferably a thermoplastic film, and preferably a film with strength properties that result in relatively uniform directional shrinking properties when the film is subjected to heat above its melt point. The film-covered stent graft is provided with punctures (slits or other apertures) through the thickness of the film, preferably at locations between adjacent stent elements as will be further described. The punctured stent-graft is then exposed to heat above the melt temperature of the film which causes the film to shrink back from the edges of the previously created puncture, resulting in openings through the wall of the stent. These openings are of size, shape, quantity and orientation that are a result of the size, shape, quantity and orientation of the previously created punctures, the amount of heat subsequently applied and the thickness and type of polymeric film used. It is apparent that these are manufacturing variables that may be controlled as desired. The resulting open area of the stent (i.e., porosity index) may cover a wide range (i.e., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or higher, or between any of these percentages). The remaining polymeric film following the heating step is in the form of polymeric webs extending between the adjacent stent elements.
An alternate method of making also involves the application of a biocompatible polymeric covering to the chosen stent form to create, temporarily, a stent-graft. A preferable stent form in this instance would be ring shaped stent elements made from a suitable balloon expandable material. The covering is similar to that described previously and may be applied to the chosen stent form similarly to the methods described in the previous section. The polymeric film covering is preferably a thermoplastic film, and preferably a film with unidirectional strength properties. The film-covered stent graft is provided with punctures (slits or other apertures) through the thickness of the film, preferably at locations between adjacent stent elements as will be further described. The punctured stent graft is then exposed to heat sufficient to bond the film to the stent form. When the resulting stent is diametrically expanded, these openings are of size, shape, quantity and orientation that are a result of the size, shape, quantity, and orientation of the previously created punctures. It is apparent that these are manufacturing variables that may be controlled as desired. The resulting open area of the stent (i.e., porosity index) may cover a wide range such as previously described. The remaining polymeric film following the puncturing/slitting step is in the form of polymeric webs extending between and interconnecting the adjacent stent elements.
Further, the finished open frame stent may optionally be provided with another covering of polymeric graft material to create a stent-graft if desired. This graft covering is easily adhered or bonded to the covering or coating that is provided over the stent elements (e.g., the wire) and forms the interconnecting webs.
The polymeric covering of these finished devices (that include a multiplicity of openings and a multiplicity of polymeric interconnecting webs) is generally continuous or substantially continuous between the stent ends, being the result of having been made from a continuous sheet of film or the result using helically wrapped polymeric tape with overlapping adjacent edges that are melt-bonded together. The film covering that forms these continuous webs is well adhered to the stent elements.
Still further, these devices may be provided with coatings (preferably elutable coatings) of various therapeutic agents (e.g., heparin) by various means known in the art that are suitable to the particular agent.
Stents made as described herein have good conformability enabled by the flexible interconnecting webs between adjacent stent elements that provide flexibility and anatomic apposition. They also have good flexural durability enabled by interconnecting webs between adjacent stent elements that mitigates fracture due to cyclic longitudinal bending in curved anatomies. The expandable device is scalable to accommodate a range of vessel sizes (e.g. 3 mm-55 mm).
The potential clinical applications of the expandable device described herein include but are not limited to: congenital defects (i.e., pulmonary artery stenosis, aortic coarctation), adjunctive aortic therapy (i.e., Type I endoleaks; aortic side branch stenting), peripheral artery disease (i.e., renal and iliac artery stenosis, aneurysm, and dissection) and venous applications.
It has been noted that a variety of stent forms may be usefully provided with the flexible connecting elements taught herein.
The helically wound serpentine wire 18 extends continuously between opposing ends of stent 10, wherein opposing apices 22a and 22b formed of wire bends of relatively small radii are interconnected by straight or relatively straight wire segments 24. The apices typically “point” in directions that are substantially parallel to the longitudinal axis 19 of the mandrel 16 and the tubular form of the stent 10, with alternating apices 22a and 22b pointing in opposite directions, that is, pointing to opposite ends of the stent. As shown by
The enlarged portion of
While various polymeric films may be suitable for use as the stent covering (or coating) material for this device, combinations of FEP (fluorinated ethylene propylene) films used in combination with ePTFE films are preferred. The preferred ePTFE films for use with these helically wound serpentine wire stents are films having multiaxial fibrillar orientations as shown by the scanning electron photomicrograph of
While, as noted, various types of films may be used for the stent covering, the described ePTFE films is preferred because of its multiaxial (within the plane of the film) strength orientation. It is strong, thin, and has excellent biocompatibility. When suitable heat is applied following slitting, the film will retract (shrink back) with good uniformity to create the openings through the polymeric stent covering and to create the flexible polymeric interconnecting webs between adjacent stent elements.
The flexible interconnecting webs 32 that result from this process typically are of wider width at their end points where they connect with the wire apices and are of comparatively narrower width in the middle of their lengths between the apices that they interconnect. Additionally, there may be a very thin, vestigial edge (36,
A preferred method of making a flexible stent is as follows. A stainless steel mandrel of diameter equal to about the inside diameter of the intended stent is obtained. The surface of the mandrel is provided with a helical wrapping of a 1″ wide tape of Kapton® Polyimide Film (DuPont, 0.002 inch thickness). A stent of the desired length and diameter made of helically wound serpentine nitinol wire is provided (wire diameter as desired). This is then wound around the Kapton covered surface of the mandrel. The end of the stent wires are secured to an adjacent winding of the stent wire using an FEP thread tied with a securing knot. The apices of the serpentine wire are aligned so that apices pointing in a common direction are aligned with and parallel to the longitudinal axis of the mandrel. The stent is then helically wrapped with a covering of a single layer of FEP tape that has been cut from FEP film (0.00015 inch thickness and about 0.75 inch width), stretched tight over the outer surface of the stent with minimal overlap of adjacent edges of the FEP tape. This FEP tape is then cigarette wrapped (wrapped in a direction perpendicular to the longitudinal axis of the mandrel) with an ePTFE film of the type described previously. This wrapping may be started by aligning a transverse edge of the film with the longitudinal axis of the mandrel and attaching it to the underlying FEP film by carefully melt-bonding the ePTFE film edge to the FEP using a heat source such as a clean soldering iron or appropriate equivalent. Six layers of the ePTFE film are wrapped around the outer surface of the stent and the film edge is trimmed along the length of the stent (i.e., parallel to the longitudinal axis of the mandrel). The film edge is secured with the previously-used heat source.
Longitudinal slits 41 are created between adjacent wire apices that are pointed in the same direction as shown by
The above construction is them placed into a suitable convection oven set at 380° C. for 11 minutes, after which it is removed from the oven and allowed to cool to approximately ambient temperature. The outer layers of ePTFE film and Kapton tape are then removed. The resulting coated stent and underlying layer of Kapton tape are then carefully removed from the mandrel. The remaining layer of Kapton tape may then be removed from the stent using a suitable tool such as small forceps or tweezers. Remaining film edges protruding beyond the ends of the stent may then be carefully trimmed in a transverse direction close to the end apices of the stent wire with a scalpel blade.
While various polymeric films may be suitable for use as the stent covering (or coating) material for this device, combinations of FEP (fluorinated ethylene propylene) films used in combination with ePTFE films are preferred. The preferred ePTFE film for this device is a uni-axial film having higher strength in one direction, with the direction primarily aligned with the longitudinal axis 61 of the stent prior to balloon expansion. This type of film is similar to that described in U.S. Pat. No. 5,476,589. A further preference would be to modify the film with an application of a discontinuous coating of FEP similar to that taught in U.S. Pat. No. 6,159,565.
The arrangement of stent rings 62 are shown in
Also shown in
The apices 22a and 22b of each ring 62 may be made to point toward one another as shown in
A preferred method of making a stent such as a stent shown in
FEP powder (Daikin America, Orangeburg N.Y.) was applied to the stent component by first stirring the powder into an airborne “cloud” in a standard kitchen-type blender and suspending the frame in the cloud until a uniform layer of powder was attached to the stent frame. The stent component was then subjected to a thermal treatment of 320° C. for approximately three minutes. This caused the powder to melt and adhere as a coating over the stent component. Each ring was coated a second time while suspending it from the opposite end and placed in 320° C. oven for 3 minutes then removed and allowed to cool to room temperature.
Seventeen layers of a thin ePTFE film provided with a discontinuous coating of FEP as previously described was then wrapped around a stainless steel mandrel measuring approx 3.43 mm. The film is applied with its high strength orientation parallel to the longitudinal axis of the stent and with the FEP side facing out. Individual stent rings were placed over the film tube and aligned. In this case, the stent rings were aligned apex to apex and separated evenly with a gap of about 2.5 mm between each ring to achieve an overall device length of about 40 mm. An additional 17 layers of the same film was applied as previously described except with the FEP side oriented down, toward the outer diameter of the stent.
The entire assembly was wound with several layers of an ePTFE thread (Part #SO24T4, WL Gore, Elkton, MD) to impart compressive forces to the underlying construct. The assembly was placed in 320° c. oven (Grieves, Model MT1000, The Grieve Corporation, Round Lake, IL) for approximately 40 minutes. The stent assembly was removed and allowed to cool to room temperature. The over-wrap was then removed and the slits were created and excess material was removed.
While particular embodiments of the present invention have been illustrated and described herein, the present invention should not be limited to such illustrations and descriptions. It should be apparent that changes and modifications may be incorporated and embodied as part of the present invention within the scope of the following claims.
This application is a continuation of U.S. application Ser. No. 15/915,453, filed Mar. 8, 2018, which is a continuation of U.S. application Ser. No. 13/349,346, filed Jan. 12, 2012, now U.S. Pat. No. 9,943,428, issued Apr. 17, 2018, which is a continuation of U.S. application Ser. No. 12/350,921, filed Jan. 8, 2009, now U.S. Pat. No. 8,926,688, issued Jan. 6, 2015, which claims the benefit of U.S. Provisional Patent Application No. 61/020,544, filed on Jan. 11, 2008, all of which are incorporated herein by reference in their entireties for all purposes.
Number | Name | Date | Kind |
---|---|---|---|
4503569 | Dotter | Mar 1985 | A |
4655771 | Wallsten | Apr 1987 | A |
4739762 | Palmaz | Apr 1988 | A |
4776337 | Palmaz | Oct 1988 | A |
4884573 | Wijay et al. | Dec 1989 | A |
5019090 | Pinchuk | May 1991 | A |
5037427 | Harada et al. | Aug 1991 | A |
5061275 | Wallsten et al. | Oct 1991 | A |
5102417 | Palmaz | Apr 1992 | A |
5104404 | Wolff | Apr 1992 | A |
5122154 | Rhodes | Jun 1992 | A |
5123917 | Lee | Jun 1992 | A |
5201757 | Heyn et al. | Apr 1993 | A |
5236447 | Kubo et al. | Aug 1993 | A |
5282824 | Gianturco | Feb 1994 | A |
5300500 | Lee et al. | Apr 1994 | A |
5314472 | Fontaine | May 1994 | A |
5330500 | Song | Jul 1994 | A |
5360443 | Barone et al. | Nov 1994 | A |
5405377 | Cragg | Apr 1995 | A |
5409495 | Osborn | Apr 1995 | A |
5443495 | Buscemi et al. | Aug 1995 | A |
5443496 | Schwartz et al. | Aug 1995 | A |
5443499 | Schmitt | Aug 1995 | A |
5449373 | Pinchasik et al. | Sep 1995 | A |
5507767 | Maeda et al. | Apr 1996 | A |
5507771 | Gianturco | Apr 1996 | A |
5549663 | Cottone, Jr. | Aug 1996 | A |
5575816 | Rudnick et al. | Nov 1996 | A |
5591195 | Taheri et al. | Jan 1997 | A |
5613979 | Trotta et al. | Mar 1997 | A |
5662703 | Yurek et al. | Sep 1997 | A |
5665115 | Cragg | Sep 1997 | A |
5674241 | Bley et al. | Oct 1997 | A |
5683448 | Cragg | Nov 1997 | A |
5693086 | Goicoechea et al. | Dec 1997 | A |
5708044 | Branca | Jan 1998 | A |
5725570 | Heath | Mar 1998 | A |
5728150 | McDonald et al. | Mar 1998 | A |
5735892 | Myers et al. | Apr 1998 | A |
5749852 | Schwab et al. | May 1998 | A |
5755774 | Pinchuk | May 1998 | A |
5756553 | Iguchi et al. | May 1998 | A |
5769884 | Solovay | Jun 1998 | A |
5769887 | Brown et al. | Jun 1998 | A |
5800456 | Maeda et al. | Sep 1998 | A |
5800515 | Nadal et al. | Sep 1998 | A |
5800521 | Orth | Sep 1998 | A |
5814063 | Freitag | Sep 1998 | A |
5824043 | Cottone, Jr. | Oct 1998 | A |
5824059 | Wijay | Oct 1998 | A |
5843092 | Heller et al. | Dec 1998 | A |
5843161 | Solovay | Dec 1998 | A |
5873906 | Lau et al. | Feb 1999 | A |
5876432 | Lau et al. | Mar 1999 | A |
5879369 | Ishida | Mar 1999 | A |
5891193 | Robinson et al. | Apr 1999 | A |
5899934 | Amundson et al. | May 1999 | A |
5906639 | Rudnick et al. | May 1999 | A |
5919225 | Lau et al. | Jul 1999 | A |
5922020 | Klein et al. | Jul 1999 | A |
5968091 | Pinchuk et al. | Oct 1999 | A |
5984957 | Laptewicz et al. | Nov 1999 | A |
6001125 | Golds et al. | Dec 1999 | A |
6004348 | Banas et al. | Dec 1999 | A |
6007545 | Venturelli | Dec 1999 | A |
6013854 | Moriuchi | Jan 2000 | A |
6015432 | Rakos et al. | Jan 2000 | A |
6016846 | Knittel et al. | Jan 2000 | A |
6022359 | Frantzen | Feb 2000 | A |
6022374 | Imran | Feb 2000 | A |
6048360 | Khosravi et al. | Apr 2000 | A |
6071307 | Rhee et al. | Jun 2000 | A |
6077296 | Shokoohi et al. | Jun 2000 | A |
6107004 | Donadio, III | Aug 2000 | A |
6123712 | Di et al. | Sep 2000 | A |
6139573 | Sogard et al. | Oct 2000 | A |
6139575 | Shu et al. | Oct 2000 | A |
6143022 | Shull et al. | Nov 2000 | A |
6146417 | Ischinger | Nov 2000 | A |
6159219 | Ren | Dec 2000 | A |
6159239 | Greenhalgh | Dec 2000 | A |
6165210 | Lau et al. | Dec 2000 | A |
6171334 | Cox | Jan 2001 | B1 |
6174328 | Cragg | Jan 2001 | B1 |
6217609 | Haverkost | Apr 2001 | B1 |
6231597 | Deem et al. | May 2001 | B1 |
6264687 | Tomonto | Jul 2001 | B1 |
6283990 | Kanesaka | Sep 2001 | B1 |
6283992 | Hankh et al. | Sep 2001 | B1 |
6287333 | Appling et al. | Sep 2001 | B1 |
6290722 | Wang | Sep 2001 | B1 |
6312458 | Golds | Nov 2001 | B1 |
6315791 | Gingras et al. | Nov 2001 | B1 |
6315792 | Armstrong et al. | Nov 2001 | B1 |
6331188 | Lau et al. | Dec 2001 | B1 |
6331190 | Shokoohi et al. | Dec 2001 | B1 |
6334868 | Ham | Jan 2002 | B1 |
6336937 | Vonesh et al. | Jan 2002 | B1 |
6340366 | Wijay | Jan 2002 | B2 |
6344054 | Parodi | Feb 2002 | B1 |
6350277 | Kocur | Feb 2002 | B1 |
6355055 | Waksman et al. | Mar 2002 | B1 |
6357104 | Myers | Mar 2002 | B1 |
6361637 | Martin et al. | Mar 2002 | B2 |
6364903 | Tseng et al. | Apr 2002 | B2 |
6387122 | Cragg | May 2002 | B1 |
6398803 | Layne et al. | Jun 2002 | B1 |
6409754 | Smith et al. | Jun 2002 | B1 |
6419685 | Di et al. | Jul 2002 | B2 |
6432133 | Lau et al. | Aug 2002 | B1 |
6436132 | Patel et al. | Aug 2002 | B1 |
6451050 | Rudakov et al. | Sep 2002 | B1 |
6461380 | Cox | Oct 2002 | B1 |
6464718 | Miller et al. | Oct 2002 | B1 |
6488701 | Nolting et al. | Dec 2002 | B1 |
6488705 | Schmitt et al. | Dec 2002 | B2 |
6497722 | Von et al. | Dec 2002 | B1 |
6500203 | Thompson et al. | Dec 2002 | B1 |
6503556 | Harish et al. | Jan 2003 | B2 |
6506202 | Dutta et al. | Jan 2003 | B1 |
6511496 | Huter et al. | Jan 2003 | B1 |
6520986 | Martin et al. | Feb 2003 | B2 |
6527739 | Bigus et al. | Mar 2003 | B1 |
6537311 | Cox et al. | Mar 2003 | B1 |
6540773 | Dong | Apr 2003 | B2 |
6540776 | Sanders et al. | Apr 2003 | B2 |
6541589 | Baillie | Apr 2003 | B1 |
6551350 | Thornton et al. | Apr 2003 | B1 |
6551352 | Clerc et al. | Apr 2003 | B2 |
6554848 | Boylan et al. | Apr 2003 | B2 |
6558414 | Layne | May 2003 | B2 |
6558415 | Thompson | May 2003 | B2 |
6565599 | Hong et al. | May 2003 | B1 |
6579305 | Lashinski | Jun 2003 | B1 |
6585755 | Jackson et al. | Jul 2003 | B2 |
6589275 | Ivancev et al. | Jul 2003 | B1 |
6589276 | Pinchasik et al. | Jul 2003 | B2 |
6602284 | Cox et al. | Aug 2003 | B2 |
6605056 | Eidenschink et al. | Aug 2003 | B2 |
6607551 | Sullivan et al. | Aug 2003 | B1 |
6616689 | Ainsworth et al. | Sep 2003 | B1 |
6620128 | Simhambhatla | Sep 2003 | B1 |
6620193 | Lau et al. | Sep 2003 | B1 |
6626939 | Burnside et al. | Sep 2003 | B1 |
6629992 | Bigus et al. | Oct 2003 | B2 |
6645239 | Park et al. | Nov 2003 | B1 |
6652574 | Jayaraman | Nov 2003 | B1 |
6652579 | Cox et al. | Nov 2003 | B1 |
6669719 | Wallace et al. | Dec 2003 | B2 |
6673103 | Golds et al. | Jan 2004 | B1 |
6689162 | Thompson | Feb 2004 | B1 |
6709454 | Cox et al. | Mar 2004 | B1 |
6712357 | Tranquilla | Mar 2004 | B1 |
6713357 | Wang et al. | Mar 2004 | B1 |
6730117 | Tseng et al. | May 2004 | B1 |
6740114 | Burgermeister | May 2004 | B2 |
6749584 | Briggs et al. | Jun 2004 | B2 |
6770087 | Layne et al. | Aug 2004 | B2 |
6770089 | Hong et al. | Aug 2004 | B1 |
6776771 | Van et al. | Aug 2004 | B2 |
6805705 | Hong et al. | Oct 2004 | B2 |
6849086 | Cragg | Feb 2005 | B2 |
6866805 | Hong et al. | Mar 2005 | B2 |
6872433 | Seward et al. | Mar 2005 | B2 |
6881216 | Di et al. | Apr 2005 | B2 |
6881221 | Golds | Apr 2005 | B2 |
6887266 | Williams et al. | May 2005 | B2 |
6893457 | Dong | May 2005 | B2 |
6923827 | Campbell et al. | Aug 2005 | B2 |
6945991 | Brodeur et al. | Sep 2005 | B1 |
6960186 | Fukaya et al. | Nov 2005 | B1 |
7105018 | Yip et al. | Sep 2006 | B1 |
7105021 | Edens et al. | Sep 2006 | B2 |
7108716 | Burnside et al. | Sep 2006 | B2 |
7112293 | Dubson et al. | Sep 2006 | B2 |
7115220 | Dubson et al. | Oct 2006 | B2 |
7118592 | Dang et al. | Oct 2006 | B1 |
7141062 | Pinchasik et al. | Nov 2006 | B1 |
7144422 | Rao | Dec 2006 | B1 |
7163533 | Hobbs et al. | Jan 2007 | B2 |
7163553 | Limon | Jan 2007 | B2 |
7186263 | Golds et al. | Mar 2007 | B2 |
7258697 | Cox et al. | Aug 2007 | B1 |
7273495 | Limon | Sep 2007 | B2 |
7288111 | Holloway et al. | Oct 2007 | B1 |
7314480 | Eidenschink et al. | Jan 2008 | B2 |
7323008 | Kantor et al. | Jan 2008 | B2 |
7329276 | Smith et al. | Feb 2008 | B2 |
7384411 | Condado | Jun 2008 | B1 |
7455687 | Saunders et al. | Nov 2008 | B2 |
7510571 | Spiridigliozzi et al. | Mar 2009 | B2 |
7540879 | Lualdi | Jun 2009 | B2 |
7578831 | Von et al. | Aug 2009 | B2 |
7686841 | Eidenschink et al. | Mar 2010 | B2 |
7691461 | Prabhu | Apr 2010 | B1 |
7704274 | Boyle et al. | Apr 2010 | B2 |
7727271 | Kujawski et al. | Jun 2010 | B2 |
7967836 | Warnack et al. | Jun 2011 | B2 |
8066667 | Hayman et al. | Nov 2011 | B2 |
8221484 | Wesselmann | Jul 2012 | B2 |
8257432 | Kaplan et al. | Sep 2012 | B2 |
8444686 | Holman et al. | May 2013 | B2 |
8585640 | Alpini et al. | Nov 2013 | B2 |
8597566 | Eskaros et al. | Dec 2013 | B2 |
8672990 | Holman et al. | Mar 2014 | B2 |
8858863 | Venturelli | Oct 2014 | B2 |
8926688 | Burkart et al. | Jan 2015 | B2 |
8979886 | Campbell et al. | Mar 2015 | B2 |
9149612 | Chuter | Oct 2015 | B2 |
9370643 | Hedberg et al. | Jun 2016 | B2 |
9370647 | Campbell et al. | Jun 2016 | B2 |
9622888 | Armstrong et al. | Apr 2017 | B2 |
9669194 | Campbell et al. | Jun 2017 | B2 |
9682219 | Venturelli | Jun 2017 | B2 |
9770352 | Kanjickal et al. | Sep 2017 | B2 |
9901715 | Cully et al. | Feb 2018 | B2 |
9943428 | Burkart et al. | Apr 2018 | B2 |
10299948 | Bohn et al. | May 2019 | B2 |
10456281 | Armstrong et al. | Oct 2019 | B2 |
10463519 | Aggerholm et al. | Nov 2019 | B2 |
10470905 | Yang et al. | Nov 2019 | B2 |
10543116 | Bohn et al. | Jan 2020 | B2 |
10568752 | Kovach et al. | Feb 2020 | B2 |
20010020181 | Layne | Sep 2001 | A1 |
20010025130 | Tomonto | Sep 2001 | A1 |
20010032009 | Layne | Oct 2001 | A1 |
20020007102 | Salmon et al. | Jan 2002 | A1 |
20020013617 | Matsutani et al. | Jan 2002 | A1 |
20020049408 | Van et al. | Apr 2002 | A1 |
20020077690 | Wang | Jun 2002 | A1 |
20020099431 | Armstrong | Jul 2002 | A1 |
20020111668 | Smith | Aug 2002 | A1 |
20020151964 | Smith et al. | Oct 2002 | A1 |
20020165601 | Clerc | Nov 2002 | A1 |
20030060756 | Hayman et al. | Mar 2003 | A1 |
20030208260 | Lau et al. | Nov 2003 | A1 |
20030236563 | Fifer | Dec 2003 | A1 |
20040019373 | Casey et al. | Jan 2004 | A1 |
20040024442 | Sowinski et al. | Feb 2004 | A1 |
20040024448 | Chang et al. | Feb 2004 | A1 |
20040030377 | Dubson et al. | Feb 2004 | A1 |
20040033364 | Spiridigliozzi et al. | Feb 2004 | A1 |
20040096532 | Dubson et al. | May 2004 | A1 |
20040096533 | Dubson et al. | May 2004 | A1 |
20040106980 | Solovay et al. | Jun 2004 | A1 |
20040143272 | Cully et al. | Jul 2004 | A1 |
20040167635 | Yachia et al. | Aug 2004 | A1 |
20040172127 | Kantor | Sep 2004 | A1 |
20040236402 | Layne et al. | Nov 2004 | A1 |
20050004647 | Bassoe | Jan 2005 | A1 |
20050010281 | Yodfat et al. | Jan 2005 | A1 |
20050125071 | Nahleili | Jun 2005 | A1 |
20050137675 | Dubson et al. | Jun 2005 | A1 |
20050154449 | Elmaleh | Jul 2005 | A1 |
20050182474 | Jones et al. | Aug 2005 | A1 |
20050186243 | Hunter et al. | Aug 2005 | A1 |
20050209672 | George et al. | Sep 2005 | A1 |
20050228480 | Douglas et al. | Oct 2005 | A1 |
20060009835 | Osborne et al. | Jan 2006 | A1 |
20060036308 | Goshgarian | Feb 2006 | A1 |
20060036311 | Nakayama et al. | Feb 2006 | A1 |
20060085065 | Krause et al. | Apr 2006 | A1 |
20060122691 | Richter | Jun 2006 | A1 |
20060184237 | Weber et al. | Aug 2006 | A1 |
20060190072 | Das | Aug 2006 | A1 |
20060259133 | Sowinski et al. | Nov 2006 | A1 |
20060266474 | Burnside et al. | Nov 2006 | A1 |
20060271091 | Campbell et al. | Nov 2006 | A1 |
20060271157 | Edens et al. | Nov 2006 | A1 |
20060271165 | Yip et al. | Nov 2006 | A1 |
20060287709 | Rao | Dec 2006 | A1 |
20060293743 | Andersen et al. | Dec 2006 | A1 |
20070055365 | Greenberg et al. | Mar 2007 | A1 |
20070073383 | Yip et al. | Mar 2007 | A1 |
20070129791 | Balaji | Jun 2007 | A1 |
20070208412 | Elmaleh | Sep 2007 | A1 |
20070239264 | Fliedner | Oct 2007 | A1 |
20070250146 | Cully et al. | Oct 2007 | A1 |
20080161901 | Heuser et al. | Jul 2008 | A1 |
20080319388 | Slattery et al. | Dec 2008 | A1 |
20090054967 | Das | Feb 2009 | A1 |
20090069878 | Weber et al. | Mar 2009 | A1 |
20090138070 | Holzer et al. | May 2009 | A1 |
20090182413 | Burkart et al. | Jul 2009 | A1 |
20090234429 | Lau | Sep 2009 | A1 |
20090283206 | Eskaros et al. | Nov 2009 | A1 |
20100069839 | Holman et al. | Mar 2010 | A1 |
20100222870 | Kaplan et al. | Sep 2010 | A1 |
20100228333 | Drasler et al. | Sep 2010 | A1 |
20110087191 | Scheuermann | Apr 2011 | A1 |
20120071912 | Campbell et al. | Mar 2012 | A1 |
20120109283 | Burkart et al. | May 2012 | A1 |
20120253380 | Venturelli | Oct 2012 | A1 |
20120330232 | Hedberg et al. | Dec 2012 | A1 |
20130018406 | Campbell et al. | Jan 2013 | A1 |
20130184807 | Kovach et al. | Jul 2013 | A1 |
20130253466 | Campbell et al. | Sep 2013 | A1 |
20140066896 | Tilson et al. | Mar 2014 | A1 |
20140066897 | Campbell et al. | Mar 2014 | A1 |
20140066898 | Cully et al. | Mar 2014 | A1 |
20140135891 | Poehlmann et al. | May 2014 | A1 |
20140142684 | Zukowski | May 2014 | A1 |
20140172066 | Goepfrich et al. | Jun 2014 | A1 |
20140276406 | Campbell et al. | Sep 2014 | A1 |
20140277331 | Ngo et al. | Sep 2014 | A1 |
20140277346 | Kanjickal et al. | Sep 2014 | A1 |
20140277374 | Kovach | Sep 2014 | A1 |
20140378896 | Venturelli | Dec 2014 | A1 |
20150133988 | Chuter | May 2015 | A1 |
20160143759 | Bohn et al. | May 2016 | A1 |
20160243340 | Campbell et al. | Aug 2016 | A1 |
20170172776 | Kanjickal et al. | Jun 2017 | A1 |
20170340464 | Kovach et al. | Nov 2017 | A1 |
20170340465 | Kanjickal et al. | Nov 2017 | A1 |
20180049898 | Armstrong et al. | Feb 2018 | A1 |
20180193177 | Burkart et al. | Jul 2018 | A1 |
20180296377 | Bohn et al. | Oct 2018 | A1 |
20190298556 | Bohn et al. | Oct 2019 | A1 |
20190388252 | Armstrong et al. | Dec 2019 | A1 |
20200253763 | Kovach et al. | Aug 2020 | A1 |
20210236314 | Bohn et al. | Aug 2021 | A1 |
20220168124 | Bohn et al. | Jun 2022 | A1 |
Number | Date | Country |
---|---|---|
101636130 | Jan 2010 | CN |
101822868 | Sep 2010 | CN |
102940543 | Feb 2013 | CN |
103561686 | Feb 2014 | CN |
103702709 | Apr 2014 | CN |
103930157 | Jul 2014 | CN |
103930158 | Jul 2014 | CN |
0745395 | Dec 1996 | EP |
0951877 | Oct 1999 | EP |
1110561 | Jun 2001 | EP |
1550477 | Jul 2005 | EP |
1927327 | Jun 2008 | EP |
09-099087 | Apr 1997 | JP |
11-299901 | Nov 1999 | JP |
2002-501404 | Jan 2002 | JP |
2005-535414 | Nov 2005 | JP |
2010-500107 | Jan 2010 | JP |
2014-520632 | Aug 2014 | JP |
2014-530045 | Nov 2014 | JP |
2015-534883 | Dec 2015 | JP |
9517223 | Jun 1995 | WO |
9526695 | Oct 1995 | WO |
9621404 | Jul 1996 | WO |
9831305 | Jul 1998 | WO |
9917680 | Apr 1999 | WO |
9934855 | Jul 1999 | WO |
0042949 | Jul 2000 | WO |
0043051 | Jul 2000 | WO |
0045741 | Aug 2000 | WO |
0049971 | Aug 2000 | WO |
0121101 | Mar 2001 | WO |
0222024 | Mar 2002 | WO |
0313337 | Feb 2003 | WO |
0307795 | Apr 2003 | WO |
0357075 | Jul 2003 | WO |
0357077 | Jul 2003 | WO |
2004016199 | Feb 2004 | WO |
2004093941 | Nov 2004 | WO |
2005096997 | Oct 2005 | WO |
2006029617 | Mar 2006 | WO |
2006081568 | Aug 2006 | WO |
2006124824 | Nov 2006 | WO |
2008019022 | Feb 2008 | WO |
2009009635 | Jan 2009 | WO |
2009066330 | May 2009 | WO |
2010037141 | Apr 2010 | WO |
2013009740 | Jan 2013 | WO |
2013040522 | Mar 2013 | WO |
2013096854 | Aug 2013 | WO |
2013162685 | Oct 2013 | WO |
2014078558 | May 2014 | WO |
2014152684 | Sep 2014 | WO |
2014158516 | Oct 2014 | WO |
2015073114 | May 2015 | WO |
2016086202 | Jun 2016 | WO |
2017204838 | Nov 2017 | WO |
2018039444 | Mar 2018 | WO |
Entry |
---|
International Search Report and Written Opinion from PCT/US2009/000144, dated May 6, 2009, 14 pages. |
Nakayama Y, Nishi S, Ueda H, et al. Fabrication of micropored elastomeric film covered stents and acute-phase performances. Development of Covered Stents 2002; 52-61. |
Nakayama, Y. et al., “Fabrication of micorpored elastomeric film-covered stents and acute-phase performances,” Development of Covered Stents, 2002; 52-61. |
Nishi, S. et al., “Newly Developed Stent Graft with Micropored and Heparin Impregnated SPU Film, Long-Term Follow-up Study in Vivo”, Interventional Neuroradiology, 7 (Suppl 1): 161-166, 2001. |
Wilson, Eric et al., “Deployment and Healing of an ePTFE Encapsulated Stent Endograft in the Canine Aorta,” Annals of Vascular Surgery, (1997), vol. 11, No. 4, pp. 354-358. |
Number | Date | Country | |
---|---|---|---|
20210361451 A1 | Nov 2021 | US |
Number | Date | Country | |
---|---|---|---|
61020544 | Jan 2008 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15915453 | Mar 2018 | US |
Child | 17397362 | US | |
Parent | 13349346 | Jan 2012 | US |
Child | 15915453 | US | |
Parent | 12350921 | Jan 2009 | US |
Child | 13349346 | US |